• 1.

    Burza S, Croft SL, Boelaert M, 2018. Leishmaniasis. Lancet 392: 951970.

  • 2.

    Pagliano P, Ascione T, Di Flumeri G, Boccia G, De Caro F, 2016. Visceral leishmaniasis in immunocompromised: diagnostic and therapeutic approach and evaluation of the recently released IDSA guidelines. Infez Med 24: 265271.

    • Search Google Scholar
    • Export Citation
  • 3.

    Fernández-Guerrero ML, Robles P, Rivas P, Mójer F, Muñíz G, de Górgolas M, 2004. Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop 90: 1116.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Pittalis S, Nicastri E, Spinazzola F, Ghirga P, De Marco M, Paglia MG, Narciso P, 2006. Leishmania infantum leishmaniasis in corticosteroid–treated patients. BMC Infect Dis 6: 177.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Valdés Delgado T, Cordero Ruiz P, Bellido Muñoz F, 2017. Visceral leishmaniasis infection in a patient with Crohn’s disease treated with azathioprine. J Crohn’s Colitis 11: 12821283.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Bosch-Nicolau P, Ubals M, Salvador F, Sánchez-Montalvá A, Aparicio G, Erra A, Martinez de Salazar P, Sulleiro E, Molina I, 2019. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression. PLoS Negl Trop Dis 13: e0007708.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Clemente WT, Mourão PHO, Lopez-Medrano F, Schwartz BS, García-Donoso C, Torre-Cisneros J, 2018. Visceral and cutaneous leishmaniasis recommendations for solid organ transplant recipients and donors. Transplantation 102 (2S Suppl 2):S8S15.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Tintore M, Vidal-Jordana A, Sastre-Garriga J, 2019. Treatment of multiple sclerosis—success from bench to bedside. Nat Rev Neurol 15: 5358.

  • 9.

    Groves A, Kihara Y, Chun J, 2013. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 328: 918.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK, 2016. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 12: 217233.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Artemiadis AK, Nikolaou G, Kolokythopoulos D, Tegos N, Terentiou A, Triantafyllou N, Papanastasiou I, 2015. Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient. Mult Scler 21: 795796.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Hernández Clares R, Sánchez Pedreño P, García Vazquez E, Carreón Guarnizo E, Meca Lallana JE, 2018. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod. Leishmaniasis cutánea agresiva en paciente con esclerosis múltiple tratada con fingolimod. Neurologia 33: 348349 (Engl Ed).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Williams E, Isles NS, Seemann T, Kilpatrick T, Grigg A, Leroi M, Howden BP, Kwong JC, 2020. Case report: confirmation by metagenomic sequencing of visceral leishmaniasis in an immunosuppressed returned traveler. Am J Trop Med Hyg 103: 19301933.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Motta AC, Arruda D, Souza CS, Foss NT, 2003. Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid. Int J Dermatol 42: 703706.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Tejura N, Kim E, Dever LL, Chew D, 2019. Case report: mucocutaneous leishmaniasis masquerading as idiopathic midline granulomatous disease. Am J Trop Med Hyg 101: 11071110.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Informe de posicionamiento terapéutico de alemtuzumab (Lemtrada®) , 2015. Available at: http://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-alemtuzumab-lemtrada.pdf. Accessed June 4, 2021.

  • 17.

    Pitini V, Cascio A, Arrigo C, Altavilla G, 2012. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia. Br J Haematol 156: 1.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Casabianca A, Marchetti M, Zallio F, Feyles E, Concialdi E, Ferroglio E, Biglino A, 2011. Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment. Infection 39: 375378.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Los-Arcos I, Aguilar-Company J, Ruiz-Camps I, 2020. Risk of infection associated with new therapies for lymphoproliferative syndromes. Riesgo de infección asociada a nuevas terapias para el tratamiento de los síndromes linfoproliferativos. Med Clin (Barc) 154: 101107.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Mattner J, Wandersee-Steinhäuser A, Pahl A, Röllinghoff M, Majeau GR, Hochman PS, Bogdan C, 2004. Protection against progressive leishmaniasis by IFN-beta. J Immunol 172: 75747582.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Kumar R et al., 2020. Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of visceral leishmaniasis. Cell Rep 30: 25122525.e9.

    • Crossref
    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 1047 1047 183
Full Text Views 28 28 5
PDF Downloads 43 43 7
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

Case Report: Leishmaniasis in a 33-Year-Old Man with Multiple Sclerosis

View More View Less
  • 1 Dermatology Department, Hospital Universitari Vall d’Hebrón, Barcelona, Spain;
  • | 2 Pneumology Department, Hospital Universitari Vall d’Hebrón, Barcelona, Spain;
  • | 3 Tropical Medicine & International Health Unit Vall d’Hebrón—Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d’Hebron, Barcelona, Spain;
  • | 4 Neurology-Neuroimmunology Service, Multiple Sclerosis Center of Catalonia (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain;
  • | 5 Microbiology Department, University Hospital Vall d’Hebrón, Barcelona, Spain
Restricted access

ABSTRACT.

Leishmaniasis is a protozoan disease caused by species of genus Leishmania. Immunosuppression increases the risk of severe clinical forms and impairs response to treatment. The expansion of the use of immunomodulatory drugs for different conditions has raised the number of these cases. In this report, we present a case of visceral leishmaniasis in a patient with multiple sclerosis (MS) under fingolimod treatment. He presented with the triad of fever, visceromegaly, and pancytopenia and was diagnosed by the presence of amastigotes in a bone marrow sample. Furthermore, we discuss the previous published cases of MS patients under different immunosuppressant therapies to highlight its risk in endemic areas and suggest a therapeutic approach.

Author Notes

Address correspondence to Pau Bosch-Nicolau, Infectious Diseases Department. Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain. E-mail: pbosch@vhebron.net

These authors contributed equally to this work.

Authors’ addresses: Alvaro Guerra-Amor, Dermatology Department, Hospital Universitari Vall d’Hebrón, Barcelona, Spain, E-mail: aguerraamor@gmail.com. Ane Lopez-Gonzalez, Pneumology Department, Hospital Universitari Vall d’Hebrón, Barcelona, Spain, E-mail: anelopez95@gmail.com. Pau Bosch-Nicolau, Juan Espinosa-Pereiro, Maria Luisa Aznar, Fernando Salvador, Adrián Sánchez-Montalvá, and Israel Molina, Tropical Medicine & International Health Unit Vall d’Hebrón - Drassanes, Infectious Diseases Department, PROSICS Barcelona, University Hospital Vall d’Hebron, Barcelona, Spain, E-mails: pau.boschnicolau@gmail.com, juan.espinosa.pereiro@outlook.es, mlaznar@vhebron.net, fmsalvador@vhebron.net, adriansanchezmontalva@gmail.com, and israelmolina@ymail.com. Breogan Rodriguez-Acevedo and Ana Zabalza, Neurology-Neuroimmunology Service, Multiple Sclerosis Center of Catalonia (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, E-mails: brodriguez@cem-cat.org and azabalza@gmail.com. Elena Sulleiro, Microbiology Department, University Hospital Vall d’Hebrón, Barcelona, Spain, E-mail: esulleir@vhebron.net.

Save